BAY 43-9006: preclinical data.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Current pharmaceutical design

• Publication date

  2002-10-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/1381612023393026PMID 12369853
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

  2001cited by this paper
• Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach.

  2001cited by this paper
• ERbB‐2 expression is rate‐limiting for epidermal growth factor–mediated stimulation of ovarian cancer cell proliferation

  2000cited by this paper
• Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

  1999cited by this paper
• Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth.

  1993cited by this paper

• Refractory Multiple Myeloma in a West Highland White Terrier: Clinical Presentations and Therapeutic Interventions

  2025cites this paper
• Three-Dimensional Hepatocyte Spheroids: Model for Assessing Chemotherapy in Hepatocellular Carcinoma

  2024cites this paper
• The molecular mechanism underlying KRAS regulation on STK31 expression in pancreatic ductal adenocarcinoma

  2024cites this paper
• Aldehyde Dehydrogenase 2 (ALDH2): a novel sorafenib target in hepatocellular carcinoma unraveled by the proteome-wide cellular thermal shift assay.

  2024cites this paper
• Small molecule-based targeted therapy in liver cancer.

  2024cites this paper
• Absorption, metabolism, and excretion of oral [14C] radiolabeled donafenib: an open-label, phase I, single-dose study in humans

  2024cites this paper
• Dual role of PID1 in regulating apoptosis induced by distinct anticancer-agents through AKT/Raf-1-dependent pathway in hepatocellular carcinoma

  2023cites this paper
• Transarterial chemoembolization with or without multikinase inhibitors for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression

  2022cites this paper
• Design and synthesis of novel ureido and thioureido conjugated hydrazone derivatives with potent anticancer activity

  2022cites this paper
• Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors

  2022cites this paper
• Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib)

  2021cites this paper
• Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.

  2020cites this paper
• Untersuchung spezifischer Inhibitoren der PI3K-Signalkaskade zur Therapie des Lymphangioms

  2020cites this paper
• Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs

  2020cites this paper
• Cancer of the Kidney

  2020cites this paper
• Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products.

  2020cites this paper
• The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.

  2020cites this paper
• Sorafenib

  2020cites this paper
• Kinase inhibitors: look beyond the label on the bottle

  2019cites this paper
• The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.

  2018cites this paper
• The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.

  2018cites this paper
• Sequence-dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action

  2018cites this paper
• The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma

  2018cites this paper
• Development and Characterization of Novel RAF Dimer Inhibitors to Target BRAFV600e Inhibitor Resistance

  2018cites this paper
• Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach.

  2017cites this paper
• Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients

  2017cites this paper
• Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma

  2017cites this paper
• The Boolean Kinetics of signal transduction

  2017cites this paper
• Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry

  2017cites this paper
• Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02

  2017cites this paper
• Sorafenib combined with HER‐2 targeted vaccination can promote effective T cell immunity in vivo

  2017cites this paper
• Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer

  2017influential citation
• Tumor angiogenesis revisited: Regulators and clinical implications

  2017cites this paper
• Effectiveness of Sorafenib in Hepatic Hemangioma

  2017cites this paper
• Cutaneous Reactions to Targeted Therapy.

  2017cites this paper
• Targeted Therapies for Hepatocellular Carcinoma

  2016cites this paper
• Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo

  2016cites this paper
• Angiogenesis Inhibition in Breast Cancer

  2016cites this paper
• Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer

  2016cites this paper
• An optimized approach in the synthesis of imatinib intermediates and analogues

  2016cites this paper
• Discovery of Potent c-MET Inhibitors with New Scaffold Having Different Quinazoline, Pyridine and Tetrahydro-Pyridothienopyrimidine Headgroups

  2016cites this paper
• Choosing the right cell line for renal cell cancer research

  2016cites this paper
• Antitumor activity of sorafenib on colorectal cancer

  2016cites this paper
• Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report

  2016cites this paper
• Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin.

  2016cites this paper
• Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib

  2015cites this paper
• The discovery and development of sorafenib for the treatment of thyroid cancer

  2015cites this paper
• Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells

  2015cites this paper
• FLT3-ITD. Clinical (Sorafenib/AC220)

  2015cites this paper
• Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1

  2015cites this paper
• Sorafenib enriches epithelial cell adhesion molecule–positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2‐AKT cascade

  2015cites this paper
• Sorafenib: 10 years after the first pivotal trial.

  2015cites this paper
• The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial

  2015cites this paper
• Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis.

  2015cites this paper
• Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.

  2015cites this paper
• Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF

  2014cites this paper
• Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use

  2014influential citation
• Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3β.

  2014cites this paper
• The Study of a Novel Sorafenib Derivative HLC-080 as an Antitumor Agent

  2014cites this paper
• Cutaneous Lymphoid Infiltrates in Patients Receiving Biologic Modifiers

  2014cites this paper
• Alteration in the Balance of Prosurvival and Proapoptotic Signalling Pathways Leads to Sequence-Dependent Synergism Between Docetaxel and Sorafenib in Human Non-small Cell Lung Cancer Cell Lines

  2014cites this paper
• BRAF inhibitors: From the laboratory to clinical trials.

  2014cites this paper
• Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.

  2014cites this paper
• Phenotypic screening in cancer drug discovery — past, present and future

  2014cites this paper
• A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).

  2014cites this paper
• Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.

  2014cites this paper
• Re‐evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel

  2014cites this paper
• Physiologically based pharmacokinetic models for everolimus and sorafenib in mice

  2013cites this paper
• A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186

  2013cites this paper
• Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

  2013cites this paper
• Chapter Twenty-Six – Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma

  2013cites this paper
• A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice.

  2013cites this paper
• Sorafenib in the Continuum of Care for Hepatocellular Carcinoma: Challenges in Defining Optimal Practice

  2013cites this paper
• Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial

  2013cites this paper
• Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update

  2013cites this paper
• Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia–Pacific region

  2013cites this paper
• Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

  2013cites this paper
• Inhibitory effects of a new 1H-pyrrolo[3,2-c]pyridine derivative, KIST101029, on activator protein-1 activity and neoplastic cell transformation induced by insulin-like growth factor-1.

  2013cites this paper
• The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.

  2013cites this paper
• Cutaneous Reactions to Novel Therapeutics

  2012cites this paper
• Sorafenib in non-small cell lung cancer

  2012cites this paper
• Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib

  2012cites this paper
• Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma

  2012cites this paper
• Polypharmacological Kinase Inhibitors: New Hopes for Cancer Therapy

  2012cites this paper
• An overview of angiogenesis and renal cell carcinoma

  2012cites this paper
• Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

  2012cites this paper
• Proteinase-activated receptors (PARs) and calcium signaling in cancer.

  2012cites this paper
• Giant cavernous hepatic hemangioma shrunk by use of sorafenib

  2012cites this paper
• Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer

  2012cites this paper
• Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.

  2012cites this paper
• Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors

  2012cites this paper
• [A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma].

  2012cites this paper
• The VHL-HIF Signaling in Renal Cell Carcinoma: Promises and Pitfalls

  2012cites this paper
• Small molecule inhibitors of BRAF in clinical trials.

  2012cites this paper
• Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.

  2012cites this paper
• Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

  2012cites this paper
• Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments

  2012cites this paper
• Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib

  2012cites this paper
• Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.

  2012cites this paper